BusinessNews

Global Myocardial Infarction Market Outlook: Drug Classes, Distribution Channels, Regional Insights, and Company Profiles (2024-2032) ⅼ Renub Research

Global Myocardial Infarction Market Overview

The global myocardial infarction market is projected to reach a value of approximately US$ 3.43 billion by 2032, with an estimated compound annual growth rate (CAGR) of 6.06% from 2024 to 2032. According to Renub Research, the market was valued at US$ 2.02 billion in 2023.

Myocardial infarction, commonly known as a heart attack, is a critical condition caused by insufficient blood flow to the heart muscle, typically due to a blockage in one or more coronary arteries. Without prompt treatment, the affected heart tissue begins to die, leading to permanent damage or death. Immediate medical intervention is essential to minimize long-term harm or fatality.

Growth Drivers in the Global Myocardial Infarction Market

Key factors contributing to the growth of the global myocardial infarction market include:

Rising Cases of Cardiovascular Diseases (CVDs)

Cardiovascular diseases (CVDs) encompass a wide range of heart and blood vessel disorders. Risk factors such as high blood pressure, high cholesterol, diabetes, smoking, obesity, and sedentary lifestyles contribute to the increasing prevalence of CVDs. The World Heart Federation reported in 2021 that over 50% of a billion people worldwide are affected by cardiovascular conditions, leading to 20.5 million deaths annually. This significant disease burden drives the demand for myocardial infarction treatments and interventions.

Advancements in Medical Technology

Technological innovations are reshaping the landscape of myocardial infarction treatment. New imaging techniques like cardiac magnetic resonance imaging (MRI) and computed tomography (CT) angiography provide detailed insights into heart structure and function. Recent approvals of new drugs, like Lodoco (colchicine) in June 2023, targeting inflammation—a key cause of atherosclerotic cardiovascular disease—further boost market growth.

Request for free Sample Report:  https://www.renub.com/request-sample-page.php?gturl=myocardial-infarction-market-p.php

Increased Public Awareness Campaigns

Public awareness initiatives play a crucial role in raising knowledge about cardiovascular diseases and promoting early detection and intervention. Campaigns like the 2023 Global Heart Hub’s Heart Failure Awareness Month and NHS’s campaign encouraging people to seek immediate help for heart attack symptoms contribute to heightened awareness and market growth.

Regional Insights

Europe

Europe is expected to hold a significant share in the global myocardial infarction market due to the high prevalence of heart-related disorders in the region. The Lancet reported that cardiovascular diseases account for 45% of all deaths in Europe. Efforts by the World Health Organization (WHO) and other bodies to address this health burden are driving market growth. Product approvals by European regulatory authorities, such as Jardiance® for heart failure treatment, further enhance the market outlook.

Key Players and Industry Developments

Leading companies in the global myocardial infarction market include Pfizer, Sanofi-Aventis/Bristol-Myers Squibb, AstraZeneca, Merck, Daiichi Sankyo, Eli Lilly and Company, Takeda, Novartis, Genentech, Amgen, Regeneron/Sanofi, and Boehringer Ingelheim. Recent industry developments that signal continued growth include:

  • Johnson & Johnson’s Clinical Presentations (April 2024): Showcasing clinical and real-world evidence from its cardiovascular portfolio at the American College of Cardiology’s 73rd Annual Scientific Session & Expo.
  • FDA Approval of Wegovy for Weight Loss (March 2024): Novo Nordisk’s drug approval to reduce cardiovascular complications in people with obesity and heart disease.
  • Philips’ AI in Cardiac Ultrasound (August 2023): Demonstrating how AI integration can enhance clinical confidence and efficiency in cardiac care.
  • Johnson & Johnson’s Acquisition of Abiomed (November 2022): The USD 16.6 billion acquisition aims to enhance cardiac innovation.
  • Traditional Chinese Medicine Study (November 2022): Research presented at the American Heart Association showed that tongxiluo, a traditional Chinese herbal ingredient, could reduce mortality risk after heart attacks by 36%.

These developments reflect ongoing efforts to improve patient care, technological advancements, and strategic business moves, indicating a robust and evolving global myocardial infarction market.

 

 

About the Company:

 

Renub Research is a Market Research and Information Analysis company with more than 15 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 9000 syndicated reports and worked on more than 750 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.

 

Media Contact:

 

Company Name: Renub Research

Contact Person: Rajat Gupta, Marketing Manager

Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)

Address: 225 Kristie Ln, Roswell, GA 30076

Email: info@renub.com

LinkedIn: https://linkedin.com/company/renub-research

Website: www.renub.com

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button